Results 31 to 40 of about 1,115 (163)

Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials

BMJ Open
Introduction Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and ciclosporin is standard of care for patients with severe aplastic anaemia (sAA) not eligible or suitable for allogeneic stem cell transplant. While patients respond to IST,
Stephane Heritier, Alisa Higgins, Piers Blombery, Robin Filshie, Paul Lacaze, Kate Wilson, William Stevenson, Lauren Young, Zoe McQuilten, Jennifer Curnow, Lucy Fox, Vanessa Fox, Ilona Cunningham, Devendra K Hiwase, Frank Firkin, Kylie Mason, Anthony K Mills, Dominic Pepperell, Sushrut Patil, Jeff Szer, Neil Waters, Stephen Ting, Erica Wood   +22 more
doaj   +3 more sources

Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA

Blood Advances
: This phase 4, multicenter, open-label study was conducted to evaluate the safety, efficacy, and treatment satisfaction of switching to avatrombopag from another thrombopoietin receptor agonist (TPO-RA) in patients with immune thrombocytopenia (ITP ...
Michael D. Tarantino, Kailash Mosalpuria, Scott Kolodny, Jessica Zhang, Michael Vredenburg, Brian D. Jamieson   +5 more
doaj   +2 more sources

Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report

Leukemia Research Reports
Patients who receive allogeneic hematopoietic stem cell transplantation (alloHSCT) are at risk for developing persistent thrombocytopenia. Here, we describe treatment with avatrombopag, a thrombopoietin receptor agonist, in a pediatric patient with ...
Emilie J. Lynch, Autumn Citta, Constance Alford, John A. Ligon, Mansi Dalal, Paul Castillo, Biljana Horn, Natalie Dotson, Giselle Moore-Higgs, Jordan Milner   +9 more
doaj   +2 more sources

Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag. [PDF]

TH Open
Objective Clinical trials indicate that avatrombopag, a thrombopoietin-receptor agonist (TPO-RA), is safe and effective for treating patients with primary immune thrombocytopenia (ITP), but real-world evidence on its broader clinical effectiveness is ...
Hill QA, Zaja F, Sánchez de Mora MDCF, Cervinek L, Janssens A, Hosnijeh FS, Le Treust L, Glen F, Putnik M, Rich C, Miesbach W.   +10 more
europepmc   +2 more sources

Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial. [PDF]

J Clin Oncol
Chemotherapy-induced thrombocytopenia (CIT) is a challenging and common complication of cytotoxic chemotherapy in patients with GI cancers. There is no widely available approved treatment.
Al-Samkari H, Shatzel JJ, Panch SR, Keating JH, Walsh EP, Weekes CD, Kardosh A, Cohen SA, Cohen JJ, Hodges PG, Dhaver SE, Strojny N, Donovan C, Belibasakis C, Soff GA.   +14 more
europepmc   +2 more sources

Cyclosporine plus avatrombopag versus cyclosporine monotherapy for first-line treatment of elderly patients with transfusion-dependent non-severe aplastic anemia: a single center retrospective study

Annals of Medicine
Background Elderly patients with transfusion-dependent non-severe aplastic anemia (TD-NSAA) face limited treatment options owing to transplantation incompatibility and safety concerns.Methods Data from older patients (≥60 years) newly diagnosed with TD ...
Zhuxin Zhang, Qinglin Hu, Leyu Wang, Chen Yang, Miao Chen, Bing Han   +5 more
doaj   +2 more sources

P131 | EVALUATION OF PLATELET RESPONSE IN CHRONIC ITP PATIENTS TREATED WITH A PERSONALIZED DOSING REGIMEN OF AVATROMBOPAG: A SINGLE-CENTER COHORT ANALYSIS

Haematologica
Introduction: ITP is an autoimmune disorder characterized by isolated thrombocytopenia caused by immune-mediated platelet destruction and insufficient platelet production, resulting in an increased bleeding risk. Thrombopoietin receptor agonists (TPO-RAs)
A. Baffioni, C. Giubbilei, G. Giustini, A.M. Vannucchi, V. Carrai   +4 more
doaj   +1 more source

Efficacy and Safety of Avatrombopag Treatment in Immune Thrombocytopenia Patients in Poland: A Multicenter Study [PDF]

TH Open
Michal Witkowski, Jagoda Rytel, Justyna Kozinska, Jolanta Oleksiuk, Weronika Piszczek, Elzbieta Wiater, Jacek Kwiatkowski, Janusz Halka, Radoslaw Bogucki, Wiktoria Ryzewska, Tadeusz Robak   +10 more
doaj   +2 more sources

Literature Review and Experts’ Opinion for Managing Thrombocytopenia in Chronic Liver Disease

Journal of Applied Hematology
Thrombocytopenia (TCP) commonly complicates chronic liver disease (CLD), with platelet transfusion traditionally serving as the standard therapeutic approach, despite associated risks such as infection, alloimmunization, and transfusion reactions. Recent
Faisal Alsayegh, Ahmed Alfadhli, Abeer Algharabally, Maen Almattooq, Salem Alshameri, Munira Altarrah, Drew Provan   +6 more
doaj   +2 more sources

Efficacy and Safety of Avatrombopag in Patients with Chronic Liver Disease and Thrombocytopenia Undergoing Elective Surgery. [PDF]

J Clin Med
Background/Objectives: The aim of this study was to evaluate the efficacy and safety of avatrombopag in patients with chronic liver disease (CLD) and thrombocytopenia scheduled for elective invasive/minimally invasive procedures, providing clinical ...
Cao W, Chen F, Hao H, Wei X, Li X, Zhang Z, Deng W, Wang S, Yao L, Gao Z, Wang S, Zhang L, Lu Y, Gao Y, Xie Y, Li M.   +15 more
europepmc   +2 more sources